RxDoctor Payments Data

Drew Siebenmorgen, PA

Physician Assistant · Little Rock, ARNPI 1093161069

Payments from drug & device makers

$1,084in general payments, 2019–2025

Across 58 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$385
  • Amgen$303
  • Novo Nordisk$146
  • Teva Pharmaceuticals USA, Inc.$60
  • Lilly USA, LLC$41
  • Amarin Pharma, Inc.$29
  • plus $121 from 7 others

What the payments were for

  • Food & beverage$1,084100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,084 in reported general payments places this provider in the 65th percentile of 451 physician assistant providers in Arkansas.

See all physician assistant providers in Arkansas

Medicare billing

Part B allowed, 2024
$12,829
Medicare patients
94
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin64$66,377
OzempicSemaglutide49$57,246
MounjaroTirzepatide30$39,531
EliquisApixaban44$39,353
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$37,880
FarxigaDapagliflozin Propanediol20$23,393
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$20,196
Varenicline Tartrate44$14,174
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$13,535
Incruse ElliptaUmeclidinium Bromide15$7,704
KerendiaFinerenone11$7,519
Albuterol Sulfate HfaAlbuterol Sulfate213$7,091
Pregabalin60$5,134
BrilintaTicagrelor11$4,995
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$16$59,11976 claims
Novo NordiskOzempic$146$57,24649 claims
Lilly USA, LLCMounjaro$41$39,53130 claims
PfizerEliquis$17$39,35344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 451 physician assistant providers in Arkansas.

Other physician assistant in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →